In selected groups of patients with atrial fibrillation, ablation can lead to an improvement in symptoms and/or prognosis. To avoid complications, anticoagulation before, during and after ablation should be criteria-driven. There is a consensus that periprocedural oral anticoagulation (OAC) is generally recommended regardless of the thromboembolic risk. On the other hand, the longer-term continuation of OAC is controversial. The ALONE-AF study published in 2025 has provided new evidence in this regard.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle
Surgical Challenges and Recurrence Patterns
- Chronic hand eczema: common, long-lasting, and distressing
Non-steroidal anti-inflammatory treatment options are essential for long-term management
- Alcohol Consumption While Taking Semaglutide
Withdrawal Symptoms Thanks to GLP-1 RA?
- Non-anginal chest pain: Could it be a heart attack?
From Triage to Secondary Prevention—A Recent Update
- Malignant oral squamous cell carcinomas (OPSCC/HNSCC)
Innovative Treatment Options
- Acne vulgaris: Topical and Systemic Treatment Options
Spotlight on “Hot Topics”
- Asthma: GINA Guidelines 2026